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Background: If asthmatic children cannot obtain sufﬁcient control of their disease, not only do they suffer
from asthma symptoms, but the daily life activities of their caregivers are also disrupted. We investigated
the effectiveness of an inhaled corticosteroid (ICS) for symptom control in previously ICS-untreated
school-aged asthmatic children as well as caregiver treatment satisfaction (CTS).
Methods: A multicenter, open-label, single-arm study on 12-week ICS (budesonide Turbuhaler®) mon-
otherapy was undertaken in subjects aged 5e15 years with bronchial asthma not treated with ICS during
the previous 3 months. At 0, 4, 8, and 12 weeks after start of ICS administration, Japanese Pediatric
Asthma Control Program (JPAC) scores, and CTS scores were summated and lung function measured. At
weeks 0 and 12, questionnaires on caregiver anxiety were also assessed.
Results: Seventy-ﬁve patients were enrolled, and 69 assessed. Ninety percent of subjects had been
treated with asthma controller medication except ICS before study enrollment. JPAC score and CTS score
were improved signiﬁcantly at weeks 4, 8, and 12 (p < 0.001). With regard to CTS, more than half of
caregivers showed a perfect score at weeks 8 and 12. There was a signiﬁcant correlation between JPAC
score and CTS score. Lung function and caregiver anxiety were also improved, and good compliance with
treatment was observed during the intervention.
Conclusions: If treating ICS-untreated school-aged asthmatic children with uncontrolled symptoms, ICS
monotherapy can improve CTS along with improving asthma control.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Dokkyo Medical University,
higi 321-0293, Japan.
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If asthmatic children cannot obtain sufﬁcient control of their
disease, not only do they suffer from asthma symptoms, but thevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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on a questionnaire developed to assess the quality of life (QoL) of
caregivers of asthma patients1 showed that caregiver QoL was
correlated with asthma control in children.2 Whether caregivers
feel conﬁdent and are satisﬁed with a child's asthma treatment is
an important factor inﬂuencing the success or failure of treatment
because the assistance of caregivers is essential for long-term
management of asthma.3
Inhaled corticosteroids (ICSs) are the ﬁrst-line treatment of
asthma for school-aged and older patients.4 In Japan over the past
decade, ICSs have been prescribed more commonly, but the prev-
alence of prescription of ICSs in asthmatic children remains low5
(presumably because of anxiety regarding their side effects6).
Thus, a non-negligible number of asthmatic children are thought to
suffer from insufﬁcient control of asthma. ICS administration is
likely to improve the asthma control and lung function of patients,
as well as caregiver treatment satisfaction (CTS). Several studies
have shown the effectiveness of ICS for the treatment of childhood
asthma.7 However, prospective studies in children with uncon-
trolled asthma focusing on asthma control and CTS in ICS mono-
therapy are lacking.
We conducted a 12-week prospective study with budesonide
Turbuhaler® (BUD-TBH) monotherapy to elucidate the effective-
ness of ICS monotherapy in asthmatic children who did not use an
ICS in the previous 3 months, and in whom previous treatment did
not enable sufﬁcient control of asthma. Asthma control by patients
was measured using the Japanese Pediatric Asthma Control Pro-
gram (JPAC) score.8,9 The relationship between CTS and symptom
control by patients was also assessed.
Methods
The present study (UMIN000005155) was conducted in accor-
dance with the principles of the Declaration of Helsinki. The study
protocol was approved by the Ethical Review Board of Dokkyo
Medical University (Tochigi, Japan).
This was a multicenter, open-label, single-arm study to evaluate
symptomatic improvement, inﬂuence on CTS, and safety after 12
weeks of switching to ICS (BUD-TBH)monotherapy in subjects aged
5e15 years with bronchial asthma who had not used an ICS in the
previous 3months. It was conducted betweenMarch 2011 and June
2012 at participating institutes.Fig. 1. Caregiver treatment satisfaction (CTS) questionnaire. The face scaleSubjects
Subjects were enrolled if they satisﬁed all of the following in-
clusion criteria: written informed consent could be obtained from
the patient and parents/guardians (for patients who were too
young to provide written informed consent, verbal assent of the
patients conﬁrmed by a parent/guardian could be substituted);
outpatients with bronchial asthma aged 5e15 years; patients who
were ICS-naïve or not treated during the preceding 3 months; pa-
tients whowere diagnosed with poorly controlled asthma based on
the JPAC questionnaire8,9 upon study enrollment; patients who
could schedule four visits with same guardian.
Patients were excluded from the study if they: had received sys-
temic corticosteroid therapy within the precedingmonth; could not
use the Turbuhaler® appropriately (as judged by the investigating
physician);were contraindicated for the study drug; had anychronic
respiratory disease other than asthma; had an acute infection of the
lower respiratory tract upon study enrollment; were judged by the
investigating physician to be inappropriate for this study.
Treatment and measurements
Subjects were treated with BUD-TBH (400 mg/day) for 12 weeks.
Any other controller medications were discontinued before study
commencement.
The JPAC score (range, 0e15) was scored as: 15 points, complete
control; 12e14, favorable (insufﬁcient) control; and 11, poor
control. CTS using a “face scale”10,11 (ﬁve grades scored from 1,
extremely dissatisﬁed to 5, extremely satisﬁed) designed originally
for this study (Fig.1), spirometry and patient-reported adherence of
inhalation (ﬁve grades: almost 100%; nearly 75%; nearly 50%; nearly
25%; almost did not) were measured 0, 4, 8, and 12 weeks after the
start of ICS administration. Allowance for deviation from a sched-
uled visit date was set as ±14 days. Standard values of spirometry
parameters were calculated using standard formulae provided by
the Japanese Society of Pediatric Pulmonology.12 At week 0 and
week 12, a questionnaire on caregiver anxiety was also assessed.
The questionnaire contained 14 questions designed originally for
this study based on a previous QoL report.1 Answers were “yes” or
“no” and multiple responses were allowed (Table 1). CTS and
caregiver anxiety questionnaire constraints had to be answered by
the same caregiver.has ﬁve grades [1 (extremely dissatisﬁed) to 5 (extremely satisﬁed)].
Table 1
Questionnaire on caregiver anxiety administered at week 0 and week 12.
(1) Faced problems within the last 3 months owing to a need to see a doctor
outside of regular hospital or clinic hours (including examinations on
Sundays and public holidays or visit to acute care facility) for an asthmatic
child.
(2) Faced problems within the last 3 months owing to a need for frequent
visits to a hospital or clinic because of an asthmatic child;
(3) Caused inconvenience in my workplace within the last 3 months owing to
lateness or absence due to an asthmatic child;
(4) Felt anxious about the length of time this lifestyle will continue;
(5) Felt anxious about the length of time I will have to shoulder the medical
costs due to an asthmatic child;
(6) Wanted to somehow improve the patient's asthma symptoms;
(7) Experienced family rifts because of an asthmatic child;
(8) Felt isolated owing to lack of someone to conﬁde in;
(9) Felt anxious about the effects of my own lack of sleep (e.g., irritability,
emotional instability) on daily life;
(10) Felt deeply concerned about the patient's future owing to asthma;
(11) Feared that the patient would die during an asthma attack;
(12) Unable to ask the doctor if I had questions;
(13) Felt dissatisﬁed with how the doctor cared for the patient, and have
repeatedly changed hospital or clinic;
(14) Have worried about the side effects of medication.
Answers are “yes” or “no”, and multiple responses are allowed.
Table 2
Patient characteristics.
n ¼ 69
Age (years) 8.8 (2.4)
BMI (kg/m2) 17.4 (2.9)
Sex Male 42 (61)
Female 27 (39)
Previous medication Any medication 62 (90)
Leukotriene receptor antagonist 54 (78)
Theophylline sustained-release formulation 12 (17)
Sodium cromoglycate 3 (4)
b2-agonist 34 (49)
Patch 23 (33)
Inhaler 11 (16)
Oral 9 (9)
None 7 (10)
Disease type Atopic 64 (93)
Non-atopic 2 (3)
Unclear 3 (4)
BMI, body mass index.
Data are the mean (SD) or number (%).
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reported.Statistical analyses
The sample size needed to detect a signiﬁcant improvement of
primary endpoint in the JPAC score was calculated to be 34. This
calculation was under the assumption that the mean scores pre-
treatment and post-treatment were 10.5 and 12.5, respectively,
and that the standard deviation was 4.0 with a signiﬁcance level of
5% (two-sided) and statistical power of 80%. We set the target
number of participants to be 100 by considering correlation ana-
lyses and study dropouts.
Baseline parameters are the mean and standard deviation for
proportional measurements and as counts for categorical measures.
The paired t-test, Wilcoxon signed rank test, or McNemar's test
were used for comparisons of measures between baseline and after
treatment. Correlations between the JPAC score and CTS score were
evaluated using Spearman's rank correlation for each visit. Corre-
lation between JPAC scores at all visits and CTS at all visits was also
evaluated. Missing data of treatment adherence at the ﬁnal visit
were complemented using the last observation carried forward
method. A value of p < 0.05 was used for all statistical tests. Sta-
tistical analyses were carried out using JMP v10.2 (SAS Institute,
Cary, NC, USA) or SPSS v18.3 (IBM, Armonk, NY, USA).Fig. 2. Changes in JPAC scores. (a) Changes in mean scores; (b) proportion changes of
control state (15 points, complete control; 12e14, favorable (insufﬁcient) control; and
11, poor control). Numbers of patients are shown in the respective partitions of bars.
The Wilcoxon signed rank test was used to compare results at 0e4, 0e8, and 0e12
weeks. ***p < 0.001.Results
Seventy-ﬁve patients were enrolled, and 69 were assessed. Four
subjects were excluded because they did not return to the hospital
after the ﬁrst visit, and two cases were excluded because of lack of
valid data (all of their visit dates deviated by >14 days from
scheduled dates). At week 8, four patients exceeded the visit
allowance, and two cases had some unanswered items in the JPAC,
so data for six out of 69 patients were excluded. At week 12, nine
cases exceeded the visit allowance, and two subjects had unan-
swered items in the JPAC, so data for 11 out of 69 patients were
excluded.
Baseline characteristics are shown in Table 2. Ninety percent of
subjects were treated with some type of asthma controller medi-
cation except an ICS before study enrollment, and 78% of them usedleukotriene receptor antagonists (LTRAs). The JPAC score was
improved signiﬁcantly at weeks 4, 8, and 12 (p < 0.001 at each visit)
(Fig. 2a). Subjects who achieved complete control had gradually
increased JPAC scores until week 12 and, by the end of the study
period, 33 (56.9%) had obtained complete control (Fig. 2b).
Spirometry parameters such as forced expiratory volume in 1 sec-
ond percent predicted (%FEV1), peak expiratory ﬂow percent pre-
dicted (%PEF), and maximum mid-expiratory ﬂow rate percent
predicted (%MMF) were improved signiﬁcantly at week 4 (Fig. 3).
CTS was increased signiﬁcantly at week 4 (p < 0.001), and 27
(39.1%), 32 (50.8%), and 35 (60.3%) were the best scores at weeks 4,
8 and 12, respectively (Fig. 4). Good adherence at the ﬁnal visit was
observed. Fifty patients (72.5%) showed “almost 100%” and 19
(27.5%) demonstrated “nearly 75%”. Improvement trends were
Fig. 3. Changes in lung function. (a) Forced expiratory volume in 1 second (FEV1) % predicted; (b) peak expiratory ﬂow (PEF) % predicted; (c) maximum mid-expiratory ﬂow rate
(MMF) % predicted. The paired t-test was used to compare results at 0e4, 0e8, and 0e12 weeks. **p < 0.01; ***p < 0.001.
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with coordination of patients moving to the upper-right area of the
panel according to time course. There was a signiﬁcant correlation
between the JPAC score and CTS (r ¼ 0.420, p < 0.001) (Fig. 5b). In
the questionnaire on caregiver anxiety, question 6 (“Wanted to
somehow improve the patient's asthma symptoms”) question 4
(“Felt anxious about the length of time this lifestyle will continue”)
and question 14 (“Have worried about the side effects of medica-
tion”) were improved signiﬁcantly at week 12 (Fig. 6). No serious
adverse events related with BUD-TBH were reported.
Discussion
We focused on: (i) the effectiveness of ICS monotherapy in a
real-life setting; (ii) satisfaction of treatment from the viewpoint of
caregivers. The latter has not been investigated sufﬁciently despite
its considerable importance in the long-term management of
asthma in children.Fig. 4. Changes in the satisfaction of treatment provided by the caregiver. Numbers of
patients are shown in the respective partitions of bars. The Wilcoxon signed rank test
was used to compare results at 0e4, 0e8, and 0e12 weeks. ***p < 0.001.Our results showed that ICS monotherapy improved asthma
control in those aged 5e15 years who had not been treated with an
ICS during the previous 3 months, and that CTS was correlated with
the asthma control of children. After 12-week administration of an
ICS, symptom control and lung function in asthmatic children and
the CTS of their caregivers improved signiﬁcantly. Some items of
the questionnaire on caregiver anxiety also improved signiﬁcantly.
Murphy et al.13 showed, in a clinical trial involving asthmatic chil-
dren (age, 2e6 years) treated with budesonide inhalation suspen-
sion, that better health status and asthma management of the child
improved the QoL and satisfaction of caregivers. Our results sug-
gested that similar relationships could be extended for school-aged
children.
The JPAC score was improved signiﬁcantly at week 4, and
increased gradually until week 12. Moreover, 57% of subjects ach-
ieved well-controlled asthma by week 12 despite even though
almost all subjects had poorly controlled asthma at baseline. Values
of lung function also exhibited signiﬁcant improvements. Reasons
for the drastic improvement in asthma control might be not only
the strong suppressive effect of budesonide on airway inﬂamma-
tion, but also because most of the subjects enrolled had received
inadequate controller therapy. Most subjects had been treated with
LTRAs before study enrollment, presumably because LTRAs are
commonly used drugs for pediatric patients with asthma on ac-
count of their efﬁcacy and high safety, even in infants aged <1
year.14 However, some patients have uncontrolled symptoms
despite LTRA treatment (as in most of the subjects in the present
study). Our results suggested that ICS monotherapy was effective
for such patients.
Our results also showed that CTS was correlated with the
asthma control of study participants, which was similar to the
relationship reported between caregivers' QoL and children's
asthma control in a study by Stelmach et al.2 In addition, no serious
adverse events caused by BUD-TBH were reported. This ﬁnding
suggests that CTS improves if the treatment can control symptoms
and if its side effects are minimal and well tolerated. Improved CTS
is thought to be associated with better compliance with treatment
in children, so further improvement in control might be expected.
Conversely, if caregivers feel that improvement in symptom control
is not sufﬁcient, they might not cooperate with children's treat-
ment adequately, and such noncompliance can lead to increased
morbidity (and even mortality). Thus, if symptoms in asthmatic
children are controlled inadequately, controller medication should
Fig. 5. Relationships between JPAC scores and scores for the satisfaction of treatment provided by the caregiver. Horizontal axes represent JPAC scores, vertical axes represent scores
for the satisfaction of treatment provided by the caregiver, and numbers of patients are shown in the respective partitions in diagrams. (a) Relationship at each visit; (b) four-visit
total assessment. The Spearman rank correlation coefﬁcient (r value) and p value are shown in the total assessment.
Fig. 6. Changes in responses to questionnaire on caregiver anxiety before and after
treatment. Number of “true” answers for each question. McNemar's test was used to
compare results at 0e12 weeks. The questionnaire contained the 14 questions shown
in Table 1, and multiple responses were permitted. **p < 0.01; ***p < 0.001 (McNemar's
test).
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good compliance with treatment.
With respect to the questionnaire on caregiver anxiety, the
proportion of caregivers having fear of side effects at week 12
(18.8%) decreased signiﬁcantly compared with that at baseline
(43.5%). In Japan, the prevalence of prescription of ICSs has been
increasing in recent years, but remains at a low level comparedwith
other countries.15 One reason for the low level could be that care-
givers have a fear of side effects such as a reduction in the rate of
growth and osteoporosis16 even though, in fact, growth reduction is
within an acceptable level17 and the incidence of osteoporosis doesnot increase in children.7 Our study showed that misconceptions
about ICSs could be dispelled if children's asthma symptoms were
controlled adequately and side effects were well tolerated. The
proportion of caregivers having anxiety about the future of the
children and disturbance in daily life was also decreased signiﬁ-
cantly, which might suggest that caregivers' QoL improved
completely.
Our study had limitations. Usually, this type of before-and-after
study design tends to enhance the effectiveness of the medication,
especially improvement in patient-reported outcomes, such as the
JPAC score in the present study. We did not try to show the effec-
tivenessof ICS in thepresent studybecause theeffectivenessof ICS for
asthmatic children has been shown, especially in randomized
parallel-group trials.7 A comparatively novel result from the present
study is that ICS monotherapy could probably be employed in non-
ICS-treated asthmatic children, but this hypothesis should be
conﬁrmed in a randomized clinical trial. Another limitation was the
lack of validation in our questionnaires except for JPAC. We consid-
ered the convenience of the patient/caregiver, and designed an
original, simple questionnaire. However, such modiﬁcations could
cause difﬁculties for comparison between the present study and
previous studies. However, we believe that the results from the pre-
sent study are useful for analyses of the correlation between symp-
tomcontrol (JPAC) andCTS,whichhavenot been reportedpreviously.
In conclusion, the present study suggests that ICS monotherapy
is effective to achieve good control of asthma symptoms in ICS-
untreated asthmatic children with uncontrolled symptoms. CTS
was shown to be correlated with symptom control in asthmatic
children. For ICS-untreated patients with uncontrolled symptoms,
our results suggested that ICS monotherapy was likely to aid
improvement of CTS as well as asthma control and lung function in
patients. Therefore, for asthma control in children, we should also
pay attention to CTS to achieve better outcomes.Acknowledgments
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